Greatly attenuated experimental autoimmune encephalomyelitis in aquaporin-4 knockout mice. by Li, Lihua et al.
UCSF
UC San Francisco Previously Published Works
Title
Greatly attenuated experimental autoimmune encephalomyelitis in aquaporin-4 knockout 
mice.
Permalink
https://escholarship.org/uc/item/22v4k5hp
Authors
Li, Lihua
Zhang, Hua
Verkman, Alan
Publication Date
2009-08-06
DOI
10.1186/1471-2202-10-94
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
BioMed CentralBMC Neuroscience
ssOpen AcceResearch article
Greatly attenuated experimental autoimmune encephalomyelitis 
in aquaporin-4 knockout mice
Lihua Li, Hua Zhang and AS Verkman*
Address: Departments of Medicine and Physiology, University of California, San Francisco, California, USA
Email: Lihua Li - Lihua.Li@ucsf.edu; Hua Zhang - Hua.Zhang@ucsf.edu; AS Verkman* - Alan.Verkman@ucsf.edu
* Corresponding author    
Abstract
Background: The involvement of astrocyte water channel aquaporin-4 (AQP4) in autoimmune
diseases of the central nervous system has been suggested following the identification of AQP4
autoantibodies in neuromyelitis optica, an inflammatory demyelinating disease.
Results: We investigated the involvement of AQP4 in disease severity in an established mouse
model of experimental autoimmune encephalomyelitis (EAE) produced by immunization with
myelin oligodendrocyte glycoprotein (MOG35–55) peptide. EAE was remarkably attenuated in
AQP4 null mice compared to identically treated wildtype mice. Whereas most wildtype mice
developed progressive tail and hindlimb paralysis, clinical signs were virtually absent in AQP4 null
mice. Brain and spinal cords from AQP1 null mice showed greatly reduced mononuclear cell
infiltration compared to wildtype mice, with relatively little myelin loss and axonal degeneration.
Conclusion: The reduced severity of autoimmune encephalomyelitis in AQP4 deficiency suggests
AQP4 as a novel determinant in autoimmune inflammatory diseases of the central nervous system
and hence a potential drug target.
Background
Aquaporin-4 (AQP4) is a water-selective channel
expressed in plasma membranes of astrocytes throughout
the central nervous system (CNS), particularly at astrocyte
foot processes at the blood-brain barrier and brain-cere-
brospinal fluid interfaces [1,2]. AQP4 facilitates water
movement in the brain and spinal cord, astrocyte migra-
tion, and neuroexcitatory phenomena (reviewed in ref.
[3]). Mice lacking AQP4 manifest remarkable phenotype
differences from wildtype mice in models of cytotoxic [4]
and vasogenic [5] cerebral edema, brain injury associated
with glial scarring [6], epilepsy [7] and cortical spreading
depression [8]. Structural data on AQP4 from electron
crystallography suggested a possible new role of AQP4 in
cell-cell adhesion [9,10], though subsequent experimen-
tal studies did not confirm this role [11].
Another potential new role for AQP4 that is unrelated to
its cell membrane water transport function was suggested
by the discovery of circulating autoantibodies against
AQP4 in most patients with the inflammatory demyeli-
nating disease neuromyelitis optica (NMO) [12]. Indirect
evidence, including correlations of NMO-IgG titer with
disease severity, and clinical benefit of plasmapheresis
and immunosuppression, has suggested that NMO-IgG
causes NMO (reviewed in refs. [13-15]). How circulating
NMO-IgG and CNS AQP4 expression promote inflamma-
tion and cause demyelinating lesions in the central nerv-
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BMC Neuroscience 2009, 10:94 http://www.biomedcentral.com/1471-2202/10/94ous system is the subject of intense speculation. Recently,
increased AQP4 expression was found in brain and spinal
cord in experimental autoimmune encephalomyelitis
(EAE), providing further support for the possible involve-
ment of AQP4 in CNS inflammation [16].
Motivated by the potential involvement of AQP4 in an
inflammatory demyelinating CNS disease, we investi-
gated the role of AQP4 in EAE using a well-established
mouse model of EAE produced by immunization with a
peptide against myelin oligodendrocyte glycoprotein
(MOG) [17]. Studies were done comparing clinical out-
come and CNS histology in wildtype vs. AQP4 knockout
mice, which have normal brain microanatomy, blood-
brain barrier integrity, and baseline intracranial pressure
[4,18,19]. We found remarkably less severe EAE in mice
lacking AQP4, providing evidence for a novel role of
AQP4 in neuroinflammation.
Results
EAE was induced in wildtype and AQP4 null mice in a
C57/bl6 genetic background by immunization with
MOG35–55 peptide. Most wildtype mice developed pro-
gressive tail and hindlimb weakness, generally seen by 16
days after the initial immunization, and progressing in
some mice to complete hindlimb paralysis. In contrast,
the AQP4 null mice did not develop clinical signs except
for transient tail weakness in one MOG-treated AQP4 null
mouse. Control wildtype and AQP4 null mice, which
were identically treated except for exclusion of MOG pep-
tide, did not develop clinical signs. Fig. 1A shows photo-
graphs of two MOG-treated wildtype and two AQP4 null
mice, demonstrating tail and hindlimb weakness in the
wildtype mice. A movie showing the difference is pro-
vided [see Additional file 1]. Fig. 1B summarizes the clin-
ical scores, which were assessed without knowledge of
genotype information, showing remarkably attenuated
EAE clinical signs in the AQP4 null mice. Fig. 1C shows
similar body weights of MOG-treated wildtype and AQP4
null mice, and control mice.
To verify that wildtype and AQP4 null mice responded
appropriately to the MOG immunizations, the right hind-
paws of a subset of mice were injected with 50 μg MOG35–
55 at 15 days after the initial immunization, according to
standard procedure [20,21]. Marked and comparable
swelling was seen in the MOG-treated wildtype and AQP4
null mice, with no swelling seen in control mice (data not
shown).
Spinal cord and brains of MOG-treated and control mice
were assessed at 32 days after initial MOG immunization.
Fig. 2A (left) shows hematoxylin and eosin staining of spi-
nal cord of MOG-treated wildtype and AQP4 null mice.
Mononuclear cell infiltrates were consistently seen in
MOG-treated wildtype mice, but were infrequent or
absent in AQP4 null mice (and absent in all control
mice). Fig. 2A (right) summarizes histological scores
obtained from assessment of sections from all mice by
two investigators who were blinded to genotype and treat-
ment information. A very significant difference was
found. Fig. 2B shows immunohistochemistry for the lym-
phocyte marker CD45. The positive staining of mononu-
clear cell infiltrates confirms their cellular identity as
lymphocytes. Fig. 2C shows staining for myelin by Luxol
Clinical assessment of mice following EAE induction by MOG peptideFigur 1
Clinical assessment of mice following EAE induction 
by MOG peptide. A. Photographs of EAE-induced wildtype 
(+/+) and AQP4 null (-/-) mice at 19 days after initial MOG 
immunization. Arrowhead, tail paralysis; arrows, hindlimb 
weakness/paralysis. See Supplemental Materials for movie. B. 
EAE clinical score (see Methods) for EAE-induced and con-
trol wildtype and AQP4 null mice. C. Mouse body weight. 
Differences in body weight gain not significant.
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BMC Neuroscience 2009, 10:94 http://www.biomedcentral.com/1471-2202/10/94fast blue. All MOG-treated wildtype mice showed multi-
ple areas of myelin loss in white mater of spinal cord, with
remarkably fewer or no areas of myelin loss in MOG-
treated AQP4 null mice.
Immunofluorescence with anti-NF200 antibody revealed
axonal loss in white mater in lesions containing cell infil-
trates where reduced myelin staining was seen (Fig. 2C,
right insets).
GFAP and AQP4 immunofluorescence is shown in Fig. 3.
AQP4 expression was seen mainly in GFAP-positive astro-
cytes in control wildtype mice. EAE induction in wildtype
mice produced increased GFAP and AQP4 expression
around lesions (demarcated by arrows), but near absence
of GFAP and AQP4 immunofluorescence within lesions.
AQP4 immunofluorescence was absent in AQP4 null
mice, as expected, though there was often seen a mild
increase in GFAP immunofluorescence.
Fig. 4A shows representative hematoxylin and eosin-
stained sections of brain (left) and a summary of histolog-
ical scores (right). As in spinal cord sections, clearly more
mononuclear cell infiltration was seen in the MOG-
Spinal cord following EAE inductionFigure 2
Spinal cord following EAE induction. A. (left) Repre-
sentative hematoxylin and eosin stained spinal cord sections 
(at L1 level) from EAE-induced wildtype (+/+) and AQP4 null 
(-/-) mice, shown at low and high (in boxes) magnifications. 
Arrows denote areas of mononuclear cell infiltration. All 
scale bars: 200 μm. (right) Histological score (see Methods) 
(S.E., p < 0.001). B. CD45 immunohistochemistry. Arrows 
denote CD45-positive lymphocytes in infiltrates. C. Luxol 
fast blue staining. Arrows denote regions of myelin loss. Left 
inset shows high magnification of Luxol fast blue staining. 
Right inset shows loss of NF200 immunofluorescence (red) 
within infiltrates (nuclei stained blue with DAPI).
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GFAP and AQP4 in spinal cordFigure 3
GFAP and AQP4 in spinal cord. GFP immunofluores-
cence (green) and AQP4 immunofluorescence (red) shown 
with DAPI (blue) stained nuclei. Representative sections 
shown from EAE-induced wildtype (+/+) and AQP4 null (-/-) 
mice, and control wildtype mice. Arrows point toward EAE 
lesion.
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Brain following EAE inductionFigure 4
Brain following EAE induction. A. (left) Representative 
hematoxylin and eosin stained brain sections from EAE-
induced wildtype (+/+) and AQP4 null (-/-) mice, and control 
(non-MOG-treated) wildtype mice. Arrows denote mononu-
clear cell infiltrates. All scale bars: 100 μm. (right) Histologi-
cal score (S.E., p < 0.001). B. CD45 immunohistochemistry. 
Arrows denote CD45-positive lymphocytes.
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BMC Neuroscience 2009, 10:94 http://www.biomedcentral.com/1471-2202/10/94treated wildtype mice. The cell infiltrates in brain were
CD45 positive (Fig. 4B), as seen in spinal cord.
Discussion
Our data show marked attenuation in the severity of EAE
in mice lacking AQP4. The reduced clinical severity, with
virtual absence of clinical signs, is consistent with the
reduced inflammatory cell infiltration in brain and spinal
cord of AQP4 null mice. Whether AQP4 is similarly
involved in other neuroinflammatory diseases of the CNS
is unknown. We previously reported improved clinical
outcome in a mouse model of bacterial meningitis, with
greatly reduced meningeal inflammation [22], though it
was not possible to isolate effects of AQP4 on inflamma-
tion versus brain water accumulation and intracranial
pressure elevation. The EAE model here is not associated
with significant brain swelling or intracranial pressure ele-
vation.
The mechanisms are not known by which AQP4 expres-
sion is associated with increased inflammation in EAE.
The association of NMO with AQP4 autoantibodies sug-
gests the possibility of a local inflammatory response
involving AQP4. Whether an immune response directly
against AQP4 occurs in EAE is not known, nor is it known
whether AQP4 expression might exacerbate the astrocyte
response to injury because of increased cell swelling and
delayed K+ uptake from the extracellular space. Another
possibility, based on AQP4 biology, is local alterations in
brain water content in the region of the inflammatory
lesions. Other possible mechanisms include AQP4-
dependent differences in the concentrations of excitatory
neurotransmitters, in astrocyte activation and migration,
and in inflammatory cell movement into lesions across
the blood-brain barrier and brain parenchyma. Investiga-
tion of these possibilities will likely present a considerable
challenge.
Conclusion
In conclusion, our studies implicate AQP4 as a novel
determinant of the severity of EAE. The increased AQP4
expression reported in EAE around inflammatory lesions
likely amplifies the response in a positive feedback man-
ner, increasing the difference in response between
wildtype and AQP4 null mice. As such, compounds that
interfere with the upregulated expression of AQP4, or per-
haps that reduce AQP4 function or plasma membrane
expression, may be of clinical benefit in selected neuroin-
flammatory diseases of the CNS.
Methods
Mice
AQP4 null mice in a C57BL/6 genetic background were
obtained by >10 back-crosses of mice generated by tar-
geted gene disruption (originally in a CD1 genetic back-
ground [18]). Studies were performed on eight-to-twelve
week old weight-matched, female C57BL/6 wildtype and
AQP4 null mice. Mice were maintained in air-filtered
cages and fed normal mouse chow in the U.C.S.F. Animal
Care facility. All procedures were approved by the U.C.S.F.
Committee on Animal Research.
Peptide
MOG35–55 (single letter amino acid code: H-MEVGWYR-
SPFSRVVHLYRNGK-OH) was synthesized by Biomatik
(Wilmington, DE). The peptide was > 98% pure.
Induction and clinical scoring of EAE
A 1:1 emulsion was made containing 400 μg MOG35–55 in
complete Fruend's adjuvant supplemented with 4 mg/ml
Mycobacterium tuberculosis H37Ra (Sigma). According to
standard procedures [20,21], mice were injected 0.1 ml of
the emulsion subcutaneously, distributed over three sites
along the midline of the back between the shoulders. Mice
were injected intravenously with 200 ng pertussis toxin 24
and 48 hours later. Control mice were treated identically
except for exclusion of MOG peptide. Mice were boosted
subcutaneously with 400 μg MOG35–55 in incomplete
Fruend's adjuvant one week after the initial immuniza-
tion. Mice were assess daily for clinical signs using the fol-
lowing scoring: 0, normal mouse; no signs of disease; 1,
limp tail or hind limb weakness, but not both; 2, limp tail
and hind limb weakness; 3, partial hind limb paralysis; 4,
complete hind limb paralysis. Eight MOG-treated
wildtype and five AQP4 null mice were used for clinical
assessment and histological studies, and four control
wildtype and four control AQP4 null mice.
Histology and immunostaining
At day 32 after initial MOG immunization, mice were
anesthetized by intraperitoneal Avertin (125 mg/kg) and
perfused transcardially with 4% paraformaldehyde in
PBS. Brain and spinal cord were removed and fixed for 24
h in 4% paraformaldehyde. Tissues were dehydrated with
increasing concentrations of ethanol, treated with clearing
agent, and embedded in paraffin. Sections were deparaffi-
nized and stained using standard procedures with hema-
toxylin and eosin, and Luxor fast blue (for myelin).
Hematoxylin and eosin-stained sections were scored for
the severity of inflammation using the following scale: 0,
no inflammation; 1, mild inflammation with few mono-
nuclear cells infiltrates; 2, marked inflammation with
multiple infiltrates per 100× field; 3, severe inflammation
with extensive infiltrates in both white and grey mater.
For CD45 immunocytochemistry, paraffin-embedded sec-
tions were cut at 5 μm thickness and deparaffinized, then
treated with citrate buffer using microwave antigen
retrieval and 3% hydrogen peroxide. Sections were incu-
bated for 2 h with a primary CD45 antibody (1:200,Page 4 of 5
(page number not for citation purposes)
BMC Neuroscience 2009, 10:94 http://www.biomedcentral.com/1471-2202/10/94Abcam), then incubated with biotinylated secondary goat
anti-rabbit antibody (1:1000, Vector Labs, Burlingame,
CA), followed by avidin-biotin peroxidase complex
(1:1000). Peroxidase labeling was visualized with diami-
nobenzidine to yield a brown color. For AQP4, GFAP and
NF200 immunofluorescence, sections were incubated
with mouse anti-GFAP (Sigma, 1:500) and rabbit anti-
AQP4 antibody (Chemicon, Temecula, CA, 1:200), or
rabbit anti-NF200 antibody (Chemicon, 1:200), and
detected by using fluorescent goat-anti-mouse and goat-
anti-rabbit secondary antibodies (1:200, Molecular
Probes). Cell nuclei were stained blue with 4',6-diamid-
ino-2-phenylindole (DAPI).
Abbreviations
AQP4: aquaporin-4; CNS: central nervous system; EAE:
experimental autoimmune encephalomyelitis; MOG:
myelin oligodendrocyte glycoprotein; NMO: neuromyeli-
tis optica; NF200: neurofilament 200; DAPI: 4',6-diamid-
ino-2-phenylindole.
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Additional file 1
Video of MOG-treated mice. Real-time video (total 8 s) of MOG-treated 
wildtype (left) and AQP4 null (right) mice at 19 days after initial 
MOG35–55 immunization.
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